Geron Corp News - GERN

Professional-Grade Tools, for Individual Investors.

Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Geron Corporation (Nasdaq: GERN), a commercial stage biopharmaceutical company, today reported that it has granted non-statutory stock options to...

Form 3 - Initial statement of beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Geron Corporation Announces Appointment of Jim Ziegler as Chief Commercial Officer

Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer...

Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Geron Corporation (Nasdaq: GERN), a commercial stage biopharmaceutical company, today reported that it has granted non-statutory stock options to...

Geron Corporation Reports Second Quarter 2024 Financial Results and Business Highlights

U.S. commercial launch of RYTELO™ (imetelstat) began in June 2024 for patients with lower-risk myelodysplastic syndromes (LR-MDS) with...

Geron Announces Updated NCCN Guidelines® Recommending RYTELO™ (imetelstat) for the Treatment of Symptomatic Anemia in Patients with Lower-Risk MDS

RYTELO, for both RS+ and RS- patients, has a Category 1 recommendation for second-line treatment and a Category 2A recommendation for first-line...

👍️0

Spike5 6 days ago

1/4 step forward and then 3 steps back . Total joke yes this is a cancer cure haha

👍️0

Spike5 1 week ago

It’s over shorts will win like I have said all along … this is done I told people what a shit company this is

👍️0

Spike5 1 week ago

If it goes under 4 it will do a RS within one year .

👍️0

learningcurve2020 2 weeks ago

Everyone's just waiting to see if there's any market penetration. Retail will be the last to know either way.

👍️0

Spike5 2 weeks ago

This company can’t even cure its own cancer . Management

👍️0

big bambino 2 weeks ago

Seeing all this price swing back and forth (with no announcement) gives credence to manipulation. JUST MY HONEST OPINION!

👍️0

attilathehunt 2 weeks ago

Probably funds reshuffling for quarter end.

👍️0

big bambino 3 weeks ago

1 1/2 hours into overtime, 550,000 shares traded, ummmmmmmmmm

👍️0

Stumblebum 3 weeks ago

The dude had the day off Gern up 8%….

👍️ 1 😀 2 🤣 1

Stumblebum 3 weeks ago

He probably works at a market maker and gets paid to bash the stock cause his employer is shorting the shares…..that’s his job

👍️ 3

luckygm 3 weeks ago

Instead of complaining all the time, why don't you buy down here at sell when it goes up 10%. You could have made a fortune doing that over the past 6 months.

👍️0

Spike5 3 weeks ago

Wow 10 % loss is a disaster . Now you know why I have not one good thing to say about this company . Management is making a killing and killing longs in the process .

👍️0

Spike5 3 weeks ago

This very well may be the dam breaking today … the shorts are going to keep driving this down to nothing . It’s a shame because this could have been a good thing but it is so poorly run and they have no news on anything coming out anytime soon . This amazes me that it cannot even get above five and now it’s going under 4 . Maybe even today

👍️0

Stumblebum 4 weeks ago

These new hires are probably salespeople to push the imetelstat drug

👍️0

Stumblebum 4 weeks ago

IMO a BO will occur next spring or summer once there is a definitive record of sales and forecast profitability…..$10 a share would be nice at the minimum

👍️0

attilathehunt 4 weeks ago

Those new stock options announced after the close for newly hired 'ee's are an incentive to stay on in the very likely event of a BO...

They will need them to stay on to ensure an orderly transition.

BO before end of year is my prediction.

👍️ 2

big bambino 4 weeks ago

closer & closer

👍️0

big bambino 4 weeks ago

getting closer 7 closer to that sub $4 mark

👍️0

Stumblebum 4 weeks ago

Ya they’re a bunch of bashing wussies

👍️0

learningcurve2020 4 weeks ago

These weepers are so lazy they don't even post the news.

>>We are thrilled to welcome Jim at this critical time when RYTELO is commercially available in the U.S. and we are seeing encouraging uptake since its launch at the end of June 2024,” said John A. Scarlett, M.D., Chairman and Chief Executive Officer

👍️0

big bambino 1 month ago

This is why I pay no attention to these weeping little girls on this board. One day movement down and "the sky is falling, cash out before it goes below $4". From June price of approx $3,40 (per-approval) to today's price of $4.60, is what about 30% increase. So with no news it fluctuates from $4.70 - $4.20 (with no manipulation at all, ha). I don't need to post daily fluctuations because I'm not looking to influence anyone. I've been here long enough to wait a few more months to see direction. The one thing I do know is, this drug is a one of a king, with phenomenal results and in due time will produce results. If your a day trader, go for it. So much quieter with my ignore button 🤣

👍️0

Spike5 1 month ago

Gee what a surprise it’s giving yesterday back . What a terrible company !

👍️0

Spike5 1 month ago

Oh wow . This is done . A 14% loss at least in less than I week of trading on a $4.75 cent stock is a total disaster and goes to show that there is no foundation for this company . You better hope that their sales are off the charts . Unfortunately shorts are going to eventually win this one they are the only ones doing anything with this stock . No one is buying .

👍️0

Spike5 1 month ago

I wish you luck . However unfortunately it is being manipulated and the shorts are never going to let go of this until it is down to nothing .

👍️0

learningcurve2020 1 month ago

Well, it is Geron after all. Fifteen years is a long time. We'll need to wait and see if revenues start rolling in or not. We should know soon.

👍️0

Spike5 1 month ago

No I do not think I will . I’m going to keep telling the truth about this company . I know democrats like you don’t like the truth

👍️0

Stumblebum 1 month ago

Then leave

👍️0

Spike5 1 month ago

But you have to see some logic in the fact that this has been going on with this company for a long time and when it gets approval after many years it’s discouraging what has happened since . I’m sorry I don’t want to be like this because I do hope their drips helps people but I’m jaded with this company and cannot find anything good to say about it .

👍️0

learningcurve2020 1 month ago

$2B l+ market isn't terrible until they can prove market penetration. A few things can happen now while we wait:

1. Some unexpected new indication for the drug gets fast tracked.

2. Some nasty side effect where the FDA puts a temporary hold on the drug.

3. Buyout.

👍️0

Spike5 1 month ago

Absolutely nothing to drive this company . FDA approval was bullshit they have nothing left and it went nowhere . They should be in at least the twenties not trying to stay in the 4’s. It’s really sad how bad this company is being managed .

👍️0

seward 1 month ago

added tiny order to flip

👍️0

Spike5 1 month ago

Oh wow ! Nothing else to say is over once it gets below 4 .

👍️0

Monksdream 1 month ago

GERN under $5

👍️0

Spike5 2 months ago

I just watch what it is doing do not follow it closely anymore . What is happening on Tuesday ?

👍️0

attilathehunt 2 months ago

Let's see what Tuesday brings!

👍️0

Spike5 2 months ago

The geron giveback … three certainties death taxes and geron giveback

👍️0

Spike5 2 months ago

Where is that bigmouth big bambino . He has been awfully quiet . Probably because like I said you have fda approval and it cannot get above 5 dollars . Once again I am not shorting this stock I have not and never will short any stock but also once again I will not say a good word about how terrible this company is being ran . And also because I already lost a lot of money on this stock .

👍️0

Spike5 2 months ago

If this gets under 4 it’s over .

👍️0

Spike5 2 months ago

Wow …. This will be down to nothing soon … this company will never be worth shit because the people running it do not want it to be . I lost money back when this company did what it is doing now . No im not shorting this stock but I’m also not going to say anything good about this company . But you have delusional idiots on this board who think this is going up to a hundred . I don’t want to see what happened to me happen to others . I’m tired of management being the only ones making money

Ok that’s funny I’ll stop my nonsense .they are going to get a buy out for billions with sales that are not even one million. The truth hurts !

👍️0

learningcurve2020 2 months ago

Stop your nonsense. They finally have revenues! Now it's only about growing pains, hopefully.

>>08:59 AM EDT, 08/08/2024 (MT Newswires) -- Geron (GERN) reported a Q2 net loss Thursday of $0.10 per diluted share, widening from a loss of $0.09 a year earlier.

Analysts polled by Capital IQ expected a per-share loss of $0.10.

Revenue for the quarter ended June 30 was $882,000, up fro $29,000 a year earlier.

Analysts surveyed by Capital IQ expected $290,000.

As of June 30, the company said it had $430.4 million in cash, cash equivalents and marketable securities, which, together with projected revenue from US sales of Rytelo, will be enough to fund its expected operating requirements into Q2 of 2026.

👍️0

Spike5 2 months ago

Well sorry to people who thought this was going somewhere… unfortunately the shorts are going to win this one .

👍️0

attilathehunt 2 months ago

Someone placed 19k on this weeks' 5 call options....They expect at least 5.10 in two days.

👍️0

Spike5 2 months ago

I have never seen a stock that cannot hold gains … it’s sad

👍️0

attilathehunt 2 months ago

Lots of call options trading today!

Someone truly likes the Jan 7 options!!

👍️0

Spike5 2 months ago

Oh boy this is going to get smashed today

👍️0

learningcurve2020 3 months ago

"Geron Announces Updated NCCN Guidelines® Recommending RYTELO™ (imetelstat) for the Treatment of Symptomatic Anemia in Patients with Lower-Risk MDS"

👍️0

seward 3 months ago

I wish I had bought every dip this year. But I loaded up on CDs instead.

Still holding 3 positions.

👍️0

Market Data

News

Trading Tools

Markets

Discover

Hot Features

Follow Feed

Options Flow

Monitor

Geron Corp (GERN)

Professional-Grade Tools, for Individual Investors.

GERN News

Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Form 3 - Initial statement of beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Geron Corporation Announces Appointment of Jim Ziegler as Chief Commercial Officer

Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Geron Corporation Reports Second Quarter 2024 Financial Results and Business Highlights

Geron Announces Updated NCCN Guidelines® Recommending RYTELO™ (imetelstat) for the Treatment of Symptomatic Anemia in Patients with Lower-Risk MDS

Geron Corporation Announces Chief Commercial Officer to Depart at End of August 2024

Geron to Announce Second Quarter 2024 Financial Results on August 8, 2024

Form 4 - Statement of changes in beneficial ownership of securities

Form 144 - Report of proposed sale of securities

Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 144 - Report of proposed sale of securities

GERN Discussion

Your Recent History

Company

Business

Popular

Get The App

Trending Now

Toplists

Market Data

News

Trading Tools

Markets

Discover

Hot Features

Follow Feed

Options Flow

Monitor

Geron Corp (GERN) News

Geron Corp (GERN)

Professional-Grade Tools, for Individual Investors.

GERN News

Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Form 3 - Initial statement of beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Geron Corporation Announces Appointment of Jim Ziegler as Chief Commercial Officer

Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Geron Corporation Reports Second Quarter 2024 Financial Results and Business Highlights

Geron Announces Updated NCCN Guidelines® Recommending RYTELO™ (imetelstat) for the Treatment of Symptomatic Anemia in Patients with Lower-Risk MDS

Geron Corporation Announces Chief Commercial Officer to Depart at End of August 2024

Geron to Announce Second Quarter 2024 Financial Results on August 8, 2024

Form 4 - Statement of changes in beneficial ownership of securities

Form 144 - Report of proposed sale of securities

Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 144 - Report of proposed sale of securities

GERN Discussion

Your Recent History

Company

Business

Popular

Get The App